
OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
m6A-RNA Demethylase FTO Inhibitors Impair Self-Renewal in Glioblastoma Stem Cells
Sarah Huff, Shashi Kant Tiwari, Gwendolyn González, et al.
ACS Chemical Biology (2021) Vol. 16, Iss. 2, pp. 324-333
Open Access | Times Cited: 133
Sarah Huff, Shashi Kant Tiwari, Gwendolyn González, et al.
ACS Chemical Biology (2021) Vol. 16, Iss. 2, pp. 324-333
Open Access | Times Cited: 133
Showing 1-25 of 133 citing articles:
m6A modification: recent advances, anticancer targeted drug discovery and beyond
Lijuan Deng, Wei-Qing Deng, Shu-Ran Fan, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 261
Lijuan Deng, Wei-Qing Deng, Shu-Ran Fan, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 261
Tumors exploit FTO-mediated regulation of glycolytic metabolism to evade immune surveillance
Yi Liu, Guanghao Liang, Hongjiao Xu, et al.
Cell Metabolism (2021) Vol. 33, Iss. 6, pp. 1221-1233.e11
Open Access | Times Cited: 241
Yi Liu, Guanghao Liang, Hongjiao Xu, et al.
Cell Metabolism (2021) Vol. 33, Iss. 6, pp. 1221-1233.e11
Open Access | Times Cited: 241
The roles and implications of RNA m6A modification in cancer
Xiaolan Deng, Ying Qing, David Horne, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 8, pp. 507-526
Closed Access | Times Cited: 179
Xiaolan Deng, Ying Qing, David Horne, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 8, pp. 507-526
Closed Access | Times Cited: 179
FTO in cancer: functions, molecular mechanisms, and therapeutic implications
Yangchan Li, Rui Su, Xiaolan Deng, et al.
Trends in cancer (2022) Vol. 8, Iss. 7, pp. 598-614
Open Access | Times Cited: 141
Yangchan Li, Rui Su, Xiaolan Deng, et al.
Trends in cancer (2022) Vol. 8, Iss. 7, pp. 598-614
Open Access | Times Cited: 141
FTO downregulation mediated by hypoxia facilitates colorectal cancer metastasis
Dan‐Yun Ruan, Ting Li, Yingnan Wang, et al.
Oncogene (2021) Vol. 40, Iss. 33, pp. 5168-5181
Open Access | Times Cited: 117
Dan‐Yun Ruan, Ting Li, Yingnan Wang, et al.
Oncogene (2021) Vol. 40, Iss. 33, pp. 5168-5181
Open Access | Times Cited: 117
N1-methyladenosine modification in cancer biology: Current status and future perspectives
Jiexin Li, Haisheng Zhang, Hongsheng Wang
Computational and Structural Biotechnology Journal (2022) Vol. 20, pp. 6578-6585
Open Access | Times Cited: 89
Jiexin Li, Haisheng Zhang, Hongsheng Wang
Computational and Structural Biotechnology Journal (2022) Vol. 20, pp. 6578-6585
Open Access | Times Cited: 89
N6-methyladenosine-mediated gene regulation and therapeutic implications
Yujiao Liu, Dan Yang, Tao Liu, et al.
Trends in Molecular Medicine (2023) Vol. 29, Iss. 6, pp. 454-467
Closed Access | Times Cited: 62
Yujiao Liu, Dan Yang, Tao Liu, et al.
Trends in Molecular Medicine (2023) Vol. 29, Iss. 6, pp. 454-467
Closed Access | Times Cited: 62
Premature ovarian insufficiency: a review on the role of oxidative stress and the application of antioxidants
Yuqian Shi, Xi-Ting Zhu, Zhang Su-na, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 50
Yuqian Shi, Xi-Ting Zhu, Zhang Su-na, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 50
Epigenetics-targeted drugs: current paradigms and future challenges
Wanlin Dai, Xinbo Qiao, Yuanyuan Fang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 28
Wanlin Dai, Xinbo Qiao, Yuanyuan Fang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 28
Writers, readers, and erasers RNA modifications and drug resistance in cancer
Di Chen, Xinyu Gu, Yeltai Nurzat, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 18
Di Chen, Xinyu Gu, Yeltai Nurzat, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 18
m6A RNA methylation and beyond – The epigenetic machinery and potential treatment options
Sabrina Garbo, Clemens Zwergel, Cecilia Battistelli
Drug Discovery Today (2021) Vol. 26, Iss. 11, pp. 2559-2574
Open Access | Times Cited: 74
Sabrina Garbo, Clemens Zwergel, Cecilia Battistelli
Drug Discovery Today (2021) Vol. 26, Iss. 11, pp. 2559-2574
Open Access | Times Cited: 74
The crosstalk between m6A RNA methylation and other epigenetic regulators: a novel perspective in epigenetic remodeling
Yanchun Zhao, Yunhao Chen, Mei Ling Jin, et al.
Theranostics (2021) Vol. 11, Iss. 9, pp. 4549-4566
Open Access | Times Cited: 73
Yanchun Zhao, Yunhao Chen, Mei Ling Jin, et al.
Theranostics (2021) Vol. 11, Iss. 9, pp. 4549-4566
Open Access | Times Cited: 73
m6A Modification: A Double-Edged Sword in Tumor Development
Runnan Gao, Mujie Ye, Baihui Liu, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 66
Runnan Gao, Mujie Ye, Baihui Liu, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 66
Biological and pharmacological roles of m6A modifications in cancer drug resistance
Zaoqu Liu, Haijiao Zou, Qin Dang, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 60
Zaoqu Liu, Haijiao Zou, Qin Dang, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 60
Identification of the Role and Clinical Prognostic Value of Target Genes of m6A RNA Methylation Regulators in Glioma
Peilin Cong, Tingmei Wu, Xinwei Huang, et al.
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 59
Peilin Cong, Tingmei Wu, Xinwei Huang, et al.
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 59
Recent Advances of m6A Demethylases Inhibitors and Their Biological Functions in Human Diseases
Ya-Zhen You, Yun-Dong Fu, Ming-Jie Huang, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 10, pp. 5815-5815
Open Access | Times Cited: 49
Ya-Zhen You, Yun-Dong Fu, Ming-Jie Huang, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 10, pp. 5815-5815
Open Access | Times Cited: 49
Rational Design and Optimization of m6A-RNA Demethylase FTO Inhibitors as Anticancer Agents
Sarah Huff, Indrasena Reddy Kummetha, Lingzhi Zhang, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 16, pp. 10920-10937
Open Access | Times Cited: 47
Sarah Huff, Indrasena Reddy Kummetha, Lingzhi Zhang, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 16, pp. 10920-10937
Open Access | Times Cited: 47
Physical Exercise Prevented Stress‐Induced Anxiety via Improving Brain RNA Methylation
Lan Yan, Ji‐an Wei, Fengzhen Yang, et al.
Advanced Science (2022) Vol. 9, Iss. 24
Open Access | Times Cited: 46
Lan Yan, Ji‐an Wei, Fengzhen Yang, et al.
Advanced Science (2022) Vol. 9, Iss. 24
Open Access | Times Cited: 46
Cancer stem cells: Recent insights and therapies
Hongyu Zhou, Licheng Tan, Beilei Liu, et al.
Biochemical Pharmacology (2023) Vol. 209, pp. 115441-115441
Closed Access | Times Cited: 31
Hongyu Zhou, Licheng Tan, Beilei Liu, et al.
Biochemical Pharmacology (2023) Vol. 209, pp. 115441-115441
Closed Access | Times Cited: 31
Advances in targeting RNA modifications for anticancer therapy
Monica Pomaville, Chuan He
Trends in cancer (2023) Vol. 9, Iss. 7, pp. 528-542
Open Access | Times Cited: 30
Monica Pomaville, Chuan He
Trends in cancer (2023) Vol. 9, Iss. 7, pp. 528-542
Open Access | Times Cited: 30
Biological roles of RNA m7G modification and its implications in cancer
Xin Zhang, Wenyan Zhu, Shuyi Shen, et al.
Biology Direct (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 30
Xin Zhang, Wenyan Zhu, Shuyi Shen, et al.
Biology Direct (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 30
2-Aminobenzothiazoles in anticancer drug design and discovery
G. Huang, Tomasz Cierpicki, Jolanta Grembecka
Bioorganic Chemistry (2023) Vol. 135, pp. 106477-106477
Closed Access | Times Cited: 29
G. Huang, Tomasz Cierpicki, Jolanta Grembecka
Bioorganic Chemistry (2023) Vol. 135, pp. 106477-106477
Closed Access | Times Cited: 29
Rational Design of RNA Demethylase FTO Inhibitors with Enhanced Antileukemia Drug-Like Properties
Pan Xiao, Zongliang Duan, Zeyu Liu, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 14, pp. 9731-9752
Closed Access | Times Cited: 29
Pan Xiao, Zongliang Duan, Zeyu Liu, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 14, pp. 9731-9752
Closed Access | Times Cited: 29
Roles and therapeutic implications of m6A modification in cancer immunotherapy
Juan Pan, Tuxiong Huang, Zhenjun Deng, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 26
Juan Pan, Tuxiong Huang, Zhenjun Deng, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 26
Emerging Role and Mechanism of the FTO Gene in Cardiovascular Diseases
Ziyang Xu, Jing Xia, Xing‐dong Xiong
Biomolecules (2023) Vol. 13, Iss. 5, pp. 850-850
Open Access | Times Cited: 26
Ziyang Xu, Jing Xia, Xing‐dong Xiong
Biomolecules (2023) Vol. 13, Iss. 5, pp. 850-850
Open Access | Times Cited: 26